Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease.
Arne CarlsenRoald OmdalLars KarlsenJan Terje KvaløyLars AabakkenØyvind SteinsbøNils BolstadDavid WarrenKnut Erik Aslaksen LundinTore GrimstadPublished in: JGH open : an open access journal of gastroenterology and hepatology (2019)
In patients with Crohn's disease, serum adalimumab of at least 6.8 mg/L was associated with biochemical disease remission based on CRP and fecal calprotectin, supporting the use of TDM to ensure disease control. Albumin should be further tested in this setting.